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Biofoundries provide an integrated infrastructure to enable the rapid design,
construction, and testing of genetically reprogrammed organisms for bio-
technology applications and research. Many biofoundries are being built and a
Global Biofoundry Alliance has recently been established to coordinate activities
worldwide.
Over the past 5 years, research institutions around the world have been establishing biofoundries
to expand their biotechnology development capacities. However, the existence of these bio-
foundries is not yet widely known within the biotechnology or broader biological research
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communities. Biofoundries aim to accelerate and enhance both
academic and translational research in engineering/synthetic
biology by promoting and enabling the beneﬁcial use of auto-
mation and high-throughput equipment including process scale-
up, computer-aided design software, and other new workﬂows
and tools. Iterative Design-Build-Test-Learn biological engineer-
ing cycles (Fig. 1) allow researchers to test large-scale genetic
designs and apply artiﬁcial intelligence (AI)/machine learning to
enhance the design process. Other goals include building a robust
engineering/synthetic biology industry as well as accelerating the
commercialization of engineering/synthetic biology and bioma-
nufacturing process engineering. One aspirational goal is to
establish biodesign rules that can be applied for the efﬁcient
reprogramming of living cells for biotechnology and biomedical
applications. Such reprogramming will also allow fundamental
insights into the complexity of living systems. In terms of
throughput, current exemplars include the Edinburgh Genome
Foundry1, which for example can process over 2000 DNA
assembly reactions per week, 20-times the throughput of a single
person without automation. At the University of Illinois at
Urbana-Champaign, iBioFAB2 can build up to 1000 TALEN
constructs per day at <$3 each, 0.3% of what it might otherwise
cost. Moreover, iBioFAB can perform multiplex genome-scale
engineering of Saccharomyces ceresvisiae in a fully automated
manner3, >10-times the throughput of a single person without
automation. Working with small companies, the London DNA
Foundry4, Singapore SynCTI Foundry5 and US DOE Agile Bio-
Foundry6 now provide cost-effective access to expensive equip-
ment and the necessary expertize for product prototyping and
commercial process validation, which are often required to secure
additional capital investment.
To enable global coordination of these efforts, 15 non-
commercial biofoundries from four continents gathered in Lon-
don in June 2018 to discuss the formation of a Global Biofoundry
Alliance (GBA) that would enable the collective to share experi-
ences and resources and work together to overcome shared
challenges and unmet scientiﬁc and engineering needs. Several
operational challenges reverberated through the June meeting.
Participants frequently expressed concerns over sustainable bio-
foundry growth and development, commenting on the high
costs of retaining staff, maintaining infrastructure, and replacing
equipment at a predictable rate. Small user bases and a limited
awareness of biofoundry capabilities among potential users cur-
rently limit the revenue streams that could eventually offset
these expenditures. High experimental costs are also a signiﬁcant
barrier for the academic community and indicate that an exten-
ded period of public investment will be necessary to enable
the beneﬁts of biofoundries to impact the broader research
community. Standards were also a key challenge with scant
software, hardware, and methodological standardization in place
to promote interoperability, efﬁciency and safety. Legal issues
associated with sharing intellectual property, physical samples,
and other resources across national and institutional boundaries
have also proven difﬁcult. Using BioFoundries effectively requires
a paradigm shift in how we do biological engineering, and
training the next generation to effectively exploit these technol-
ogies is also extremely important. Notwithstanding these chal-
lenges, it was agreed that biofoundry capabilities are a critical
enabling technology for individual countries to develop capability
and deliver on the signiﬁcant promise of synthetic/engineering
biology.
The GBA will be formally launched on 9th May, 2019 in Kobe,
Japan, during a meeting of the Founding Members (Fig. 2).
The GBA has agreed to a non-binding Memorandum of
Understanding, which does not establish any legal rights or
obligations, but is a voluntary arrangement dependent upon
goodwill and cooperation. Signing parties are research institu-
tions, research funding agencies, or other entities that operate
non-commercial biofoundries, as well as other organizations that
actively support public-funded biofoundries. The parties have
non-overlapping missions with for-proﬁt entities. The objectives
of the GBA are to
(1) Develop, promote, and support non-commercial biofoun-
dries established around the world,
(2) Intensify collaboration and communication among
biofoundries,
(3) Collectively develop responses to technological, operational,
and other types of common challenges,
(4) Enhance visibility, impact and sustainability of non-
commercial biofoundries, and
(5) Explore globally relevant and societally impactful grand
challenge collaborative projects.
Fig. 1 The Design-Build-Test-Learn (DBTL) biological engineering cycle. In
simple terms the DBTL framework aims to fulﬁll particular design criteria
for a synthetic biology application, which might for example be the
production of a speciﬁc product at an optimal titer or the detection of a
speciﬁc clinical biomarker using an engineered gut microbiome. The cycle
begins with D (Design), which deﬁnes the desired target function/
speciﬁcations and involves the computational design of genetic parts,
circuits, regulatory and metabolic pathways to whole genomes; B (Build)
involves the physical assembly of those designed genetic components; T
(Test) involves the prototyping and testing of the assembled genetic
designs in living cells (also called "chasses") at different scales, which also
includes comprehensive analytical measurements (‘‘omics’’) of speciﬁc
cellular components. This can also include testing components in cell-free
extract systems; L (Learn) is the application of modeling and computational
learning tools, which uses the data obtained in T to inform the design
process. Iterations of the DBTL cycle results in genetic designs that aim to
fulﬁll the design speciﬁcations established in D. In the ﬁgure the DBTL
cycle is depicted around an imagined biofactory or bioreﬁnery where
many products will be produced using more sustainable and circular
economic processes forming the future infrastructure for a global
bioeconomy. (Credit: Christopher Johnson, DOE Agile BioFoundry, Golden,
CO, USA)
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To achieve these objectives, the GBA will provide coordination
between Alliance members and promote collective action and
sharing of pre-competitive infrastructure, open standards, pro-
tocols, best practices, bio-parts, and data where possible. This will
also involve exploring standardized legal tools to reduce the
transaction costs of sharing including the OpenMTA7. The GBA
will also allow increased visibility about the role and importance
of biofoundries by reporting on success stories and positive
impacts. Other activities will involve the exchange of sustainable
business models, as well as approaches to lowering transaction
and operational costs and expanding user bases; and personnel
exchanges, including developing teaching and training programs
for researchers and users of biofoundry facilities. The GBA will
actively and transparently engage a broad range of stakeholders
including policy makers, industry, public funding and govern-
ment agencies, as well as civil society to continually improve GBA
activities and practices.
To strengthen the coordination and collaboration within the
GBA, the Alliance will also explore opportunities to tackle a
globally relevant, societally impactful grand challenge (e.g.,
directly addressing one of the UN sustainable development goals)
with each biofoundry bringing its unique strengths and cap-
abilities to the problem. GBA members will also explore bilateral
collaborations on smaller-scale projects (e.g., biofoundry perfor-
mance testing and benchmarking). The beneﬁts of the GBA are
anticipated to be analogous to those experienced by the synthetic
yeast genome Sc2.08 project, in which internationally distributed
participant teams share a common scientiﬁc and engineering
biodesign goals.
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